Gerard Brett

Ger Brett, the founder and chief executive of Zerusa, and Liam Mulloy, the chief financial officer of the firm, previously worked in Boston Scientific.

Gerard Brett, the chief executive, and Liam Mulloy, the chief financial officer, previously worked for Boston Scientific.

Chief Executive Officer, Gerard Brett

Gerard has led the Zerusa organization from the initial formation stages of the company, it's fund raising activities, the development of the company's Guardian® hemostasis valve and future products which are under development.Prior to Zerusa, Ger worked at Boston Scientific Ireland, Galway facility.He held senior management positions in project and production management and was the Program Manager for the Taxus drug eluting stent program.Before Boston Scientific, he was employed in the United States at Ciba-Geigy Corporation in product development, technology transfer, marketing and commercialization.He received a B.S. in Chemistry from Kingston University in the United Kingdom, M.S. in Organic Chemistry from Florida State University, U.S.A., and an Marketing MBA from Auburn University, U.S.A..
...
Chief Executive Officer, Gerard Brett

Ger Brett, Chief Executive Officer of Zerusa Limited, commented: "This distribution agreement with Vascular Solutions is an important milestone in further developing market acceptance for the innovative Guardian Hemostasis Valve.
...
Chief Executive Officer, Ger Brett commented, "We are all quite pleased with the introduction of our first product, the Guardian hemostasis valve, into the medical device market.
...
Chief Executive Officer, Ger Brett commented, "Coronary Interventions is an outstanding course which offered challenging live cases, insightful lectures and question and answer sessions for the audience.

Ger Brett

To obtain further information and/or to receive an information pack, please contact Gerard Brett or Liam Mulloy at 091 861611 or e-mail us on liam.mulloy@zerusa.com.
...
Contact: Gerard BrettPhone Number: +353-91-863061

December 3, 2005 - Zerusa Limited Announces United States Food & Drug Administration Marketing Clearance for the Guardian Hemostasis Valve

Galway, Ireland, December 3, 2005.Zerusa Limited announced today that it has received United States Food & Drug Administration (FDA) 510(k) Marketing Clearance for its Guardian hemostasis valve.The Company will be implementing a market evaluation plan to assess the Guardian in the U.S. market.Upon completion of market evaluation cases the Company plans to stage geographical introductions within the U.S.

"We are very pleased to receive U.S. FDA Marketing Clearance for our first product, the Guardian hemostasis valve" said Gerard Brett, Chief Executive Officer of Zerusa Limited.
...
Contact: Gerard BrettPhone Number: +353-91-863061
...
Gerard Brett, CEO of Zerusa, said: "We're delighted to have been chosen as the regional winner of the Seedcorn competition for Connacht.
...
Contact: Gerard BrettPhone Number: +353-91-863061

September 30, 2005 - Zerusa Limited Announces thirty two European Union Clinical Cases Completed with the Guardian Hemostasis Valve

Galway, Ireland, September 30, 2005.Zerusa Limited announced today that it has now completed thirty two successful human cases involving the Guardian hemostasis valve in the European Union.

"The Guardian has proven to be an exciting new entrant into the hemostasis valve market.Interventional cardiologists have favorably commented on the Guardian's time saving operation and ease-of-use and its ability to significantly reduce the amount of blood within the surgical field.We are excited about the Guardian's prospects within the European market and other worldwide markets for the future," said Gerard Brett, Chief Executive Officer of Zerusa Limited.
...
Contact: Gerard BrettPhone Number: +353-91-863061

July 29, 2005 - Zerusa Limited Announces Receipt of the CE Mark for the GuardianÔ hemostasis valve for use in Interventional Procedures.

Galway, Ireland, July 29, 2005.Zerusa Limited announced today that it has received the CE Mark for its Guardian device, a next generation hemostasis valve.The Company plans to launch the product in European and other international markets.

"We are very pleased to receive European CE Mark approval for our first product, the Guardian" said Gerard Brett, Chief Executive Officer of Zerusa Limited.
...
Contact: Gerard BrettPhone Number: +353-91-863061
...
Contact: Gerard BrettPhone Number: +353-91-863061